Clinical Trials Logo

Type 1 Hyperlipoproteinemia clinical trials

View clinical trials related to Type 1 Hyperlipoproteinemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT01675154 Terminated - Clinical trials for Type 1 Hyperlipoproteinemia

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

Start date: November 2015
Phase: Phase 2
Study type: Interventional

Funding Source - FDA OOPD This study is being done to find out whether an investigational (not approved by FDA ) drug called SLx-4090 or Orlistat (FDA approved medication for weight loss) when given alone or in combination can treat the high blood fat (elevated triglycerides)levels found in the condition Type 1 Hyperlipoproteinemia (T1HLP) better or more safely than low fat diet alone, the current standard medical care. It is also not clear whether Orlistat, that is FDA approved for weight loss, is effective in lowering blood fat levels in patients with Type 1 hyperlipoproteinemia (T1HLP). The researchers are interested in learning whether any one of these drugs when given alone or in combination is more effective and safe in treating T1HLP.